Precision BioSciences Sues Lonza for Patent Infringement | GenomeWeb

NEW YORK (GenomeWeb News) – Precision BioSciences said today that it is suing Lonza Group and a number of its affiliates for patent infringement.

The lawsuit, filed in the US District Court for the District of Delaware, alleges that Switzerland-based Lonza's import and sale of its GS Xceed Gene Expression System and CHOK1SV knock-out cell line in the US infringes US Patent No. 8,377,674, which applies to Precision Bio's Directed Nuclease Editor genome editing technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.